Literature DB >> 34400042

Von Willebrand Disease: Current Status of Diagnosis and Management.

Angela C Weyand1, Veronica H Flood2.   

Abstract

Von Willebrand disease (VWD) is a common bleeding disorder, affecting male and female individuals equally, that often manifests in mucosal bleeding. VWD can be secondary to a quantitative (Type 1 and Type 3) or qualitative (Type 2) defects in Von Willebrand factor (VWF). Initial testing includes VWF antigen, as well as a platelet binding assay to differentiate between qualitative and quantitative defects. Further subtyping requires additional testing and is needed to ensure appropriate treatment. Desmopressin, antifibrinolytics, hormonal treatments for heavy menstrual bleeding, and VWF concentrates are commonly used in the treatment of VWD.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bleeding; Coagulation factors; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2021        PMID: 34400042      PMCID: PMC8919990          DOI: 10.1016/j.hoc.2021.07.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  91 in total

1.  Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII.

Authors:  P CORNU; M J LARRIEU; J CAEN; J BERNARD
Journal:  Br J Haematol       Date:  1963-04       Impact factor: 6.998

2.  The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor.

Authors:  H Pergantou; P Xafaki; E Adamtziki; P Koletsi; A Komitopoulou; H Platokouki
Journal:  Haemophilia       Date:  2012-05       Impact factor: 4.287

3.  Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Authors:  E Holm; K Steen Carlsson; S Lövdahl; A E Lail; T C Abshire; E Berntorp
Journal:  Haemophilia       Date:  2018-04-06       Impact factor: 4.287

4.  A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Authors:  Flora Peyvandi; Giancarlo Castaman; Paolo Gresele; Raimondo De Cristofaro; Piercarla Schinco; Antonella Bertomoro; Massino Morfini; Gabriella Gamba; Giovanni Barillari; Víctor Jiménez-Yuste; Cristoph Königs; Alfonso Iorio; Augusto B Federici
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

5.  von Willebrand factor is an acute phase reactant in man.

Authors:  B E Pottinger; R C Read; E M Paleolog; P G Higgins; J D Pearson
Journal:  Thromb Res       Date:  1989-02-15       Impact factor: 3.944

6.  Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.

Authors:  Peter A Kouides; Vanessa R Byams; Claire S Philipp; Sidney F Stein; John A Heit; Andrea S Lukes; Nyasha I Skerrette; Nicole F Dowling; Bruce L Evatt; Connie H Miller; Sally Owens; Roshni Kulkarni
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

7.  Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.

Authors:  E Berntorp; J Windyga
Journal:  Haemophilia       Date:  2009-01       Impact factor: 4.287

8.  Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations.

Authors:  Annette Timm; Jan Fahrenkrug; Henrik L Jørgensen; Henriette P Sennels; Jens P Goetze
Journal:  Eur J Haematol       Date:  2014-03-18       Impact factor: 2.997

9.  Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease.

Authors:  M Makris; B Colvin; V Gupta; M L Shields; M P Smith
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

10.  Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial.

Authors:  Marni Kwiecien; Alison Edelman; Mark D Nichols; Jeffrey T Jensen
Journal:  Contraception       Date:  2003-01       Impact factor: 3.375

View more
  1 in total

Review 1.  Endothelium, Platelets, and Coagulation Factors as the Three Vital Components for Diagnosing Bleeding Disorders: A Simplified Perspective with Clinical Relevance.

Authors:  Abhinav Bhattarai; Sangam Shah; Sara Bagherieh; Omid Mirmosayyeb; Sangharsha Thapa; Sandip Paudel; Pawan Gyawali; Pitambar Khanal
Journal:  Int J Clin Pract       Date:  2022-08-27       Impact factor: 3.149

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.